Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jan;10(1):30-34.
doi: 10.21037/jtd.2017.12.42.

Heart-breaking aspirin interruption

Michel Zeitouni  1 , Gilles Montalescot  1
Affiliations
Editorial

Heart-breaking aspirin interruption

Michel Zeitouni et al. J Thorac Dis. 2018 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: G Montalescot has received research grants or honorarium from ADIR, Amgen, AstraZeneca, Bayer, Berlin Chimie AG, Boehringer Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Cardiovascular Research Foundation, Celladon, CME Resources, Daiichi-Sankyo, Eli-Lilly, Europa, Elsevier, Fédération Française de Cardiologie, Fondazione Anna Maria Sechi per il Cuore, Gilead, ICAN, Janssen, Lead-Up, Menarini, Medtronic, MSD, Pfizer, Sanofi-Aventis, Servier, The Medicines Company, TIMI Study Group, WebMD. M Zeitouni has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Risk ratio of major adverse cardiovascular events in trials evaluating aspirin (6-17).
See this image and copyright information in PMC

Comment on

References

    1. Dewilde WJ, Oirbans T, Verheugt FW, et al. WOEST study investigators Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-15. 10.1016/S0140-6736(12)62177-1 - DOI - PubMed
    1. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-22. 10.1016/S0140-6736(13)61720-1 - DOI - PubMed
    1. Sundström J, Hedberg J, Thuresson M, et al. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events A Swedish Nationwide, Population-Based Cohort Study. Circulation 2017;136:1183-92. 10.1161/CIRCULATIONAHA.117.028321 - DOI - PubMed
    1. Saito Y, Okada S, Ogawa H, et al. The long-term therapy with low-dose aspirin did not reduce cardiovascular events in patients with type 2 diabetes in primary prevention: 10-year follow-up of a randomized controlled trial. Circulation 2017;135:659-70. 10.1161/CIRCULATIONAHA.116.025760 - DOI - PubMed
    1. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840. 10.1136/bmj.a1840 - DOI - PMC - PubMed

LinkOut - more resources